Understanding racial disparities in health care expenditures for cervical cancer [0.03%]
理解宫颈癌医疗费用的种族差异
Jerusha Daggolu,Marjan Zakeri,Sujit Sansgiry
Jerusha Daggolu
Background: Cervical cancer demonstrates a notable efficacy in treatment, evidenced by a 92% 5-year survival rate among cases diagnosed at a localized stage. In 2020, the estimated annual national expenditure for cervical...
Total cost of care of Medicare Advantage beneficiaries participating in an appointment-based model in a national pharmacy chain [0.03%]
一家全国性连锁药店开展预约模型中Medicare Advantage受益人的护理总成本
Heidi Luder,Josilaida Lawrence,Shirley Musich et al.
Heidi Luder et al.
Background: The appointment-based model (ABM) is a pharmacy service to improve medication-related health outcomes. ABM involves medication synchronization and medication review, plus other services such as medication reco...
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective [0.03%]
从美国支付方视角分析生物类似物adalimumab纳入药品报销名单的影响分析
Stephen Chaplin,Joris van Stiphout,Anna Chen et al.
Stephen Chaplin et al.
Background: The biosimilar market is growing rapidly, as evidenced by 41 approvals and 37 launches to date. As adalimumab biosimilars launch in the United States, competition among biosimilar and reference adalimumab will...
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting [0.03%]
美国医疗保险覆盖的慢性淋巴细胞白血病患者初治阶段使用维奈克拉-奥妥珠单抗与布鲁顿酪氨酸激酶抑制剂的医疗费用比较研究
Scott F Huntington,Beenish S Manzoor,Dureshahwar Jawaid et al.
Scott F Huntington et al.
Background: Bruton's tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor venetoclax in combination with obinutuzumab (VEN-O) are both recommended as frontline therapy in chronic lymphocytic leukemia (CLL). However,...
Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatments [0.03%]
治疗持续时间和频率对阿尔茨海默症治疗方法的价值和成本效益价格的影响
Soeren Mattke,Tabasa Ozawa,Mark Hanson
Soeren Mattke
Background: Disease-modifying Alzheimer treatments are becoming available. The value of the treatments will be attenuated by their complexity of delivery and monitoring, creating additional medical cost and caregiver burd...
Stakeholder perspectives on the sustainability of the United States biosimilars market [0.03%]
美国生物类似药市场的可持续性各利益相关者视角分析
Sean D Sullivan,Sophia Z Humphreys,David Fox et al.
Sean D Sullivan et al.
Biologic therapies play a critical role in modern medical practice but also present challenges for payers, patients, and other stakeholders because of their high cost. Biosimilars can mitigate the cost pressures of reference biologic therap...
How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes [0.03%]
新药采用对美国医疗体系在替代支付模式下对新药的补偿的影响：索格列净对患有心力衰竭和糖尿病患者的经济模型测量的新药影响案例分析
Jason Shafrin,Shanshan Wang,Jaehong Kim et al.
Jason Shafrin et al.
Background: Heart failure (HF) is among the leading causes of death in the United States. Further, patients hospitalized because of HF with comorbid diabetes mellitus (DM) are at a significantly increased risk of death an...
Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program [0.03%]
遗传性血液疾病管理的优化：AMCP市场洞察计划的研究成果
Terry Richardson,Michelle Rice,Ryan Haumschild et al.
Terry Richardson et al.
In this market insights program, AMCP brought together a panel of experts representing various stakeholders: national and regional health plans, integrated health care systems, employer benefits groups, clinical experts, the Centers for Dis...
Impact of mental health in persons living with rare disease: Findings from the AMCP Market Insights Program [0.03%]
罕见病患者的心理健康影响因素：来自AMCP市场洞察项目的发现
Terry Richardson,Michelle Rice,Maureen Ellen Lyon et al.
Terry Richardson et al.
Within the framework of its Market Insights Program, AMCP convened a panel of experts representing diverse stakeholders to identify alterations to plan design and/or coverage options geared toward improving the diagnosis and treatment of me...
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative [0.03%]
评估专科疾病状态下患者报告的依从性和结果：一项双站点倡议
E Danielle Bryan,Chelsea P Renfro,Rebekah H Anguiano et al.
E Danielle Bryan et al.
Background: Patient-reported outcomes (PROs) are often used by clinicians to evaluate patient response to specialty medications used to treat multiple sclerosis (MS) and rheumatologic conditions. Identifying associations ...